The University of Cincinnati has enrolled the first patients in a new clinical trial that will test the effectiveness of an investigational drug for prosthetic joint infections (PJI).

The University of Cincinnati has enrolled the first patients in a new clinical trial that will test the effectiveness of an investigational drug for prosthetic joint infections (PJI).

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.